European Union

Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update

Retrieved on: 
Tuesday, December 7, 2021
European Union, GBA, Forward-looking statement, GLOBE, Technology, Degenerative disease, Lists of diseases, Multiple sclerosis, Drug discovery, Krabbe disease, Neurodegeneration, Psychosine, Brain, Patient, Therapy, Glycogen storage disease, Champaign County, Illinois, College, University, The Michael J. Fox Foundation, Program, Galactosylceramidase, Nasdaq, MJFF, Pharmaceutical industry, Medical device

BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced a scientific update on the companys Krabbe disease program.

Key Points: 
  • BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced a scientific update on the companys Krabbe disease program.
  • Gain is developing allosteric regulators to stabilize the galactosylceramidase (GALC) enzyme and reduce psychosine disease causing toxic substrate, potentially providing the first treatment option to patients with this devastating disease.
  • These data provide additional validation of our approach in treating lysosomal storage diseases, said Eric Richman, Chief Executive Officer of Gain.
  • Krabbe disease, also known as globoid cell leukodystrophy, is a genetic disease that affects the central and peripheral nervous systems.

$2.57 Billion Electronic Shelf Label Markets by Product Type, Display Type, Component, Communication Technology, End User - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 7, 2021
Other Manufacturing, Manufacturing, European Union, QR, Automation, Growth, TFT, Smartphone, Union, AR, Paper, Wi-Fi, Bluetooth, LCD, Efficiency, Software, ESL, CAGR, Government, Time, Component, Adoption, Black, RFID, AI, NFC, Information and communications technology, Video game, Retail, Video game console

The "Electronic Shelf Label Market by Product Type, Display Type, Component, Communication Technology, End User, and Geography - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Electronic Shelf Label Market by Product Type, Display Type, Component, Communication Technology, End User, and Geography - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Electronic Shelf Labels Market is expected to reach a value of $2.57 billion by 2028, at a CAGR of 21.8% during the forecast period 2021-2028.
  • The e-paper segment is expected to account for the largest share of the electronic shelf labels market in 2021.
  • Based on the end user, the electronic shelf labels market is segmented into retail, automotive retail, manufacturing, and other end users.

EQT Says Concern Over LNG Misguided, Notes a Ramped U.S. LNG Program Represents the Biggest Green Initiative on the Planet

Retrieved on: 
Tuesday, December 7, 2021
European Union, NYSE, Company, Carbon, Climate change, EQT, Natural gas, Letter, Coal, Union, Elizabeth Warren, CEO, Industry, Methane, Plant, Coal mining, Renewable energy

"We strongly agree with the goal of keeping energy affordable and reliable for citizens of the United States.

Key Points: 
  • "We strongly agree with the goal of keeping energy affordable and reliable for citizens of the United States.
  • EQT has worked toward this goal for decades," said Mr. Rice in EQT's response letter.
  • According to Mr. Rice, if the United States wants to be a leader in addressing climate change, the country needs a ramped LNG program.
  • "LNG exports have the potential to be the biggest green initiative on the planet, and it's not even close" said Mr. Rice.

Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe

Retrieved on: 
Tuesday, December 7, 2021
EMA, European Union, Medication, Company, Comment, Medicine, CEST, Distal renal tubular acidosis, Biotechnology, NICE, Disease, Union, Quality of life, Patient, Lists of diseases, Partnership, National Institute, ADV, Neurology, NHS, Life, Health care, Kidney disease, Renal tubular acidosis, Euronext Paris, Anatomical terms of location, Cystinuria, Ageing, CEE, National Institute for Health and Care Excellence, MHRA, Marketing, Czech Republic, Sale, Central and Eastern Europe, Kidney, United Kingdom, National Health Service, Pharmaceutical industry

Advicenne is now in discussions with the National Institute for Health and Care Excellence (NICE) for the coverage and reimbursement of its treatment.

Key Points: 
  • Advicenne is now in discussions with the National Institute for Health and Care Excellence (NICE) for the coverage and reimbursement of its treatment.
  • The Medicines & Healthcare products Regulatory Agency (MHRA) recently granted marketing authorisation for Sibnayal in the UK.
  • Additionally, Advicenne has signed its first two exclusive distribution agreements for Sibnayal in the European Union.
  • Its lead product SibnayalTM (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK.

DGAP-News: GRR Group successfully initiates ESG turnaround / Specialists for local shopping properties grow in difficult market environment

Retrieved on: 
Tuesday, December 7, 2021
European Union, Environment, DGAP, ESG, Climate change, Growth, Contract, Union, Disclosure, Industry, Board, Insurance, Goal, Supermarket, News, GRR, Investment, Security (finance), Retail, Financial services, Renewable energy, Real estate

Nuremberg, 07.12.2021: The GRR Group is developing successfully even in the challenging environment of the Corona pandemic.

Key Points: 
  • Nuremberg, 07.12.2021: The GRR Group is developing successfully even in the challenging environment of the Corona pandemic.
  • The properties are held in four self-initiated open-ended special AIFs as well as in service and individual mandates.
  • At the same time, we initiated the ESG turnaround and developed a new fund to drive our sustainability strategy.
  • The demand for ESG-compliant properties that promise higher profitability in the long term is constantly increasing," explains Martin Fhrlein, member of the GRR Group Executive Board.

DGAP-News: Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic

Retrieved on: 
Tuesday, December 7, 2021
European Union, U.S. Securities and Exchange Commission, Physician, DGAP, PCR, Company, Large intestine, IVDR, Neoplasm, Health, SEC, Laboratory, Population, Mortality, FIT, Security (finance), Forward-looking statement, Union, CRC, Private Securities Litigation Reform Act, Death, Colorectal cancer, Patient, Colon, Real-time polymerase chain reaction, Biomarker, DNA, Prospectus, Cancer, American Cancer Society, Trial of the century, COVID-19, Ageing, Program, FDA, NASDAQ, Sale, News, Compliance, U.S. FDA, Pharmaceutical industry, Vaccine, Colorectal Cancer, Mainz Biomed N.V., COLOALERT, COLORECTAL CANCER, MAINZ BIOMED N.V.

At-home Colorectal Cancer Diagnostic Test Now Available Online in GermanyBERKELEY, US - MAINZ, Germany - DECEMBER 7th, 2021 -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days.
"In recent years, the largest decreases in CRC mortality have been in countries with long-standing screening programs, and we are excited to bring ColoAlert, a unique, easy-to-use diagnostic test that is highly efficacious to market," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "As we launch ColoAlert across Europe through partnerships with regional laboratories, we are mindful that the Coronavirus pandemic has made it difficult to access CRC testing via in-person physician visits. As such, we are excited to leverage our in-house lab in Mainz, Germany, to provide an efficient CRC screening alternative to ensure that anyone in the country interested in performing a test has access to a top-tier solution."
This direct-to-patient program will utilize Mainz Biomed's own, high-throughput, clinical lab based in Mainz, and be administered by in-house physicians. The Company's clinical team will also be on hand to provide phone-based support to ensure a high level of patient care. In line with Mainz Biomed's business strategy, it is expected that ColoAlert.de and other Company-owned online points of sale will eventually distribute orders for diagnostic tests to partner labs within the network, both within Germany and globally as further regulatory approvals are secured and member labs integrated.
Colorectal cancer is the second deadliest cancer in the European Union (EU), with approximately 170,000 people dying every year, out of a diagnosed population of 370,000. According to Digestive Cancers Europe*, if the European Union was able to diagnose more patients in stage 1 from the current 13% to 50%, 130,000 more lives could be saved per year and more than 3 billion € in healthcare budget savings could be generated every year, and possibly the same amount in social and work-related value.
*https://www.digestivecancers.eu/wp-content/uploads/2020/02/466-Document-... ColoAlert

Key Points: 
  • BERKELEY, US - MAINZ, Germany - DECEMBER 7th, 2021 -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the launch of ColoAlert.de , an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test.
  • This direct-to-patient program will utilize Mainz Biomed's own, high-throughput, clinical lab based in Mainz, and be administered by in-house physicians.
  • The Company's clinical team will also be on hand to provide phone-based support to ensure a high level of patient care.
  • ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy**.

Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic

Retrieved on: 
Tuesday, December 7, 2021
European Union, U.S. Securities and Exchange Commission, Physician, PCR, Company, Large intestine, IVDR, Neoplasm, Health, SEC, Laboratory, Population, Colon, GLOBE, Mortality, FIT, Security (finance), Forward-looking statement, Union, CRC, Private Securities Litigation Reform Act, Death, Patient, Colorectal cancer, DNA, Real-time polymerase chain reaction, Â, Biomarker, Prospectus, Cancer, American Cancer Society, Trial of the century, COVID-19, Ageing, FDA, NASDAQ, Sale, Compliance, U.S. FDA, Pharmaceutical industry, Vaccine

As we launch ColoAlert across Europe through partnerships with regional laboratories, we are mindful that the Coronavirus pandemic has made it difficult to access CRC testing via in-person physician visits.

Key Points: 
  • As we launch ColoAlert across Europe through partnerships with regional laboratories, we are mindful that the Coronavirus pandemic has made it difficult to access CRC testing via in-person physician visits.
  • This direct-to-patient program will utilize Mainz Biomeds own, high-throughput, clinical lab based in Mainz, and be administered by in-house physicians.
  • The Companys clinical team will also be on hand to provide phone-based support to ensure a high level of patient care.
  • ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy**.

Progress on share buyback programme

Retrieved on: 
Tuesday, December 7, 2021
European Union, FATCA, CDP, ESG, COVID-19, Climate change, Lung compliance, ING, Morning Star, Union, Failure, STOXX, S&P Global Ratings, Annual report, ING Group, Biophysical environment, Social, Internet, Life, FTSE Russell, United, Legislation, International, Social Security Government Pension Offset, New, Turnaround ADR, Risk, Table, Risk management

The purpose of ING Bank is empowering people to stay a step ahead in life and in business.

Key Points: 
  • The purpose of ING Bank is empowering people to stay a step ahead in life and in business.
  • ING Banks more than 57,000 employees offer retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).
  • Sustainability forms an integral part of INGs strategy, evidenced by INGs leading position in sector benchmarks by Sustainalytics and MSCI and our A-list rating by CDP.

MedX Health to Present at the SNN Network Canada Virtual Event December 7 – 9, 2021

Retrieved on: 
Monday, December 6, 2021
Software, Biotechnology, Pharmaceutical, Oncology, Health, Medical Devices, Technology, Other Technology, European Union, Physician, Global Health Corps, Company, Dermatology, Light, Technology, Moles, Union, Therapeutic Goods Administration, Food, TSX Venture Exchange, TSX, Medarex, Telehealth, Regulation of tobacco by the U.S. Food and Drug Administration, Health Canada, Medical device

MedX Health Corp. (TSXV: MDX) (MedX or the Company), a global leader in teledermatology, is pleased to announce its participation in the SNN Network Canada Virtual Event, taking place virtually December 7th 9th, 2021.

Key Points: 
  • MedX Health Corp. (TSXV: MDX) (MedX or the Company), a global leader in teledermatology, is pleased to announce its participation in the SNN Network Canada Virtual Event, taking place virtually December 7th 9th, 2021.
  • MedX President Dermatological Services, Mike Druhan, will present the Companys vision for scaling global access to its unique dermatological image capture technology and fully integrated telemedicine platform, DermSecure.
  • The conference will be a live, interactive online event where investors are invited to ask the Company questions in real-time.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.

Transaction in Own Shares

Retrieved on: 
Monday, December 6, 2021
Withdrawal, Royal Dutch Shell, Listing Rules, European Union, Company, Market abuse, Union, European Union (Withdrawal) Act 2018, European Union (Withdrawal Agreement) Act 2020, Online gambling

These share purchases form part of the Company's share buy-back arrangement previously announced on 02 December 2021.

Key Points: 
  • These share purchases form part of the Company's share buy-back arrangement previously announced on 02 December 2021.
  • In respect of this arrangement, BNP Paribas Exane will make trading decisions in relation to the Companys securities independently of the Company for a period from 02 December 2021 up to and including 28 January 2022.
  • In accordance with EU MAR and UK MAR, a full breakdown of the individual trades made by BNP Paribas Exane on behalf of the Company as a part of the buy-back arrangement is detailed below.
  • LEI number of Royal Dutch Shell plc: 21380068P1DRHMJ8KU70